Takeda files for azilsartan fixed-dose combo in US
This article was originally published in Scrip
Takeda has submitted a US NDA for a fixed-dose combination of azilsartan medoxomil and chlorthalidone. The product is the first to combine an angiotensin II antagonist with chlorthalidone, a long-acting thiazide-like diuretic first introduced in the 1960s and available generically.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context